Education
About Us
Working with TipRanks
Follow Us
RxSight (RXST)
NASDAQ:RXST
RXST Stock Chart & Stats
$8.24
-$1.16(-3.26%)
At close: 4:00 PM EST
$8.24
-$1.16(-3.26%)
Day’s Range― - ―
52-Week Range$6.32 - $55.57
Previous CloseN/A
Volume110.15K
Average Volume (3M)826.01K
Market Cap
$346.97M
Enterprise Value$313.89M
Total Cash (Recent Filing)$227.49M
Total Debt (Recent Filing)$11.71M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Nov 06, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding40,915,962
10 Day Avg. Volume789,689
30 Day Avg. Volume826,015
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)4.75
Price to Sales (P/S)9.55
P/FCF Ratio-59.69
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue2.00
Enterprise Value/Gross Profit2.92
Enterprise Value/Ebitda-8.90
Forecast
1Y Price Target
$8.83Price Target Upside7.16% Upside
Rating ConsensusHold
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Growth StrategyRxSight remains confident in its long-term growth trajectory, supported by both favorable demographic trends and the evolving reimbursement landscape.
Market ExpansionWith strong clinical outcomes that not only support LAL adoption but also expand the overall premium IOL market, the company maintains an optimistic longer term.
Bears Say
Financial GuidanceRXST lowered its fiscal year guidance and now expects revenue in the range of $120.0M- $130.0M, which is a decrease from the previous range.
Revenue PerformanceRXST reported revenue of $33.6M, which was below initial consensus estimates and BTIG's estimate.
RxSight News
RXST FAQ
What was RxSight’s price range in the past 12 months?
RxSight lowest stock price was $6.32 and its highest was $55.57 in the past 12 months.
What is RxSight’s market cap?
RxSight’s market cap is $346.97M.
When is RxSight’s upcoming earnings report date?
RxSight’s upcoming earnings report date is Nov 06, 2025 which is in 18 days.
How were RxSight’s earnings last quarter?
RxSight released its earnings results on Aug 07, 2025. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.254 by -$0.036.
Is RxSight overvalued?
According to Wall Street analysts RxSight’s price is currently Undervalued.
Does RxSight pay dividends?
RxSight does not currently pay dividends.
What is RxSight’s EPS estimate?
RxSight’s EPS estimate is -0.38.
How many shares outstanding does RxSight have?
RxSight has 40,915,962 shares outstanding.
What happened to RxSight’s price movement after its last earnings report?
RxSight reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.254. Following the earnings report the stock price went down -7.702%.
Which hedge fund is a major shareholder of RxSight?
Currently, no hedge funds are holding shares in RXST
RxSight Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.83 (7.16% Upside)
$8.83 (7.16% Upside)
Blogger Sentiment
Bullish
RXST Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 760.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.26%
12-Months-Change
Fundamentals
Return on Equity
-11.66%
Trailing 12-Months
Asset Growth
1.15%
Trailing 12-Months
Company Description
RxSight
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
RXST Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted positive aspects such as increased LAL revenue, improved gross margin, and international market expansion. However, significant challenges were noted including overall revenue decline, decreased LDD sales, increased net loss, and higher operating expenses. The guidance for a revenue decline further contributed to the cautious outlook.View all RXST earnings summariesRXST Stock 12 Month Forecast
Average Price Target
$8.83
▲(7.16% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Butterfly Network
―
NeuroPace
―
Ceribell, Inc.
―
Ownership Overview
5.63% Insiders
16.86% Mutual Funds
0.16% Other Institutional Investors
62.09% Public Companies and
Individual Investors